Edition:
India

Aeterna Zentaris Inc (AEZS.OQ)

AEZS.OQ on NASDAQ Stock Exchange Capital Market

0.44USD
4 Aug 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.44
Open
--
Day's High
--
Day's Low
--
Volume
20,938
Avg. Vol
399,402
52-wk High
$2.57
52-wk Low
$0.37

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris Announces Strategic Review And Engagement Of Financial Advisor
Wednesday, 13 Mar 2019 

March 12 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES STRATEGIC REVIEW AND ENGAGEMENT OF FINANCIAL ADVISOR.AETERNA ZENTARIS INC - SPECIAL COMMITTEE HAS APPROVED ENGAGEMENT BY COMPANY OF TORREYA AS ITS FINANCIAL ADVISOR.AETERNA ZENTARIS - TORREYA IS WORKING WITH MANAGEMENT TO ASSIST SPECIAL COMMITTEE AND BOARD OF DIRECTORS IN CONSIDERING A WIDE RANGE OF TRANSACTIONS.AETERNA ZENTARIS INC - CONSIDERING POTENTIAL SALE OF COMPANY.AETERNA ZENTARIS - CONSIDERING OPPORTUNITIES FOR LICENSE OF MACIMORELIN OUTSIDE OF U.S. AND CANADA, OTHER MONETIZATION DEALS RELATING TO MACIMORELIN.  Full Article

Aeterna Zentaris Receives Positive CHMP Opinion On Macimorelin For Diagnosis Of Adult Growth Hormone Deficiency
Monday, 19 Nov 2018 

Nov 19 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS (AEZS) RECEIVES POSITIVE CHMP OPINION OF MACIMORELIN FOR DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY.AETERNA ZENTARIS INC - RECOMMENDATION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION.  Full Article

Aeterna Zentaris Qtrly Loss Per Share $0.15
Wednesday, 7 Nov 2018 

Nov 6 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS REPORTS THIRD QUARTER 2018 FINANCIAL AND OPERATING RESULTS.QTRLY LOSS PER SHARE $0.15.Q3 REVENUE $663,000 VERSUS $241,000.  Full Article

Aeterna Zentaris Announces Novo Nordisk To Acquire Rights To Macrilen In U.S. And Canada
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Aeterna Zentaris Inc ::AETERNA ZENTARIS ANNOUNCES NOVO NORDISK TO ACQUIRE RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - NOVO NORDISK WILL ACQUIRE FROM STRONGBRIDGE BIOPHARMA PLC ITS RIGHTS TO MACRILEN IN UNITED STATES AND CANADA.AETERNA ZENTARIS INC - HAS LICENSED RIGHTS TO MACRILEN™ IN UNITED STATES AND CANADA TO STRONGBRIDGE BIOPHARMA.  Full Article

BRIEF-Lind Global Macro Fund Reports 9.9% Passive Stake In Aeterna Zentaris Inc As Of July 2

* LIND GLOBAL MACRO FUND LP REPORTS 9.9% PASSIVE STAKE IN AETERNA ZENTARIS INC AS OF JULY 2 - SEC FILING Source text: [https://bit.ly/2VX6xiS] (Reuters.Briefs@thomsonreuters.com)